A nimal models of human illness provide tools to dissect pathogenesis at a molecular level. The MRL-Fas lpr model is notably valuable because autoimmune disease in this strain is spontaneous, predictable, and steadily progressive and shares features with human lupus (1) (2) (3) . The hallmarks of disease in this strain consist of a profound lymphoproliferation; a massive increase in immunoglobulins (Ig), including a multitude of autoantibodies (autoAb); and rapid, fatal autoimmune kidney destruction (50% mortality, 6 mo of age) (4) . As in human lupus, multiple tissues, kidney, salivary and lacrimal glands, skin, and lungs are infiltrated by leukocytes (1, 5) . Kidney damage in the MRL-Fas lpr mice is complex and dependent on T cells. Several T cell populations promote injury in this strain, including CD4, CD8, and the unique double-negative T cells expressing B cell determinants (DN) (6) . These autoreactive T cell populations that promote lupus nephritis are highly regulated (7) . Thus, identifying the signals that control autoreactive T cell activation and clonal expansion is central to understanding mechanisms that are responsible for lupus nephritis.
T cells require at least two distinct signals for full activation (8, 9) . The first signal is provided by the engagement of the T cell receptor (TCR) with MHC plus peptide complex on antigenpresenting cells (APC), and the second "co-stimulatory" signal is collectively provided by engagement of one or more T cell co-stimulatory receptors with their specific ligands on APC (10, 11) . Signaling through the TCR alone, without a co-stimulatory signal, can lead to prolonged T cell unresponsiveness, i.e., anergy (9) . The co-stimulatory signal provided by interaction of CD28 on T cells with either B7-1 or B7-2 on APC is well characterized (12, 13) . The CD28/CTLA4 -B7-1/B7-2 T cell costimulatory pathway is a complex pathway that positively and negatively regulates T cell activation (14) . Blocking this pathway is beneficial in mouse lupus: (1) B7-1/B-2 null MRL-Fas lpr mice are protected from lupus nephritis (15), (2) CD28 null MRL-Fas lpr mice have diminished nephritis as compared with WT strains (16) , and (3) provision of CTLA4Ig (a fusion protein that binds to B7 and blocks this pathway) in the MRL-Fas lpr and NZB ϫ NZW F1 hybrid female strains reduces kidney disease (17, 18) . Thus, the B7-1/B7-2-CD28 pathway governs the tempo of renal disease in strains with lupus. The CD28 receptor family of molecules is expanding. ICOS is a recently identified CD28 homolog that is upregulated on activated T cells and resting memory T cells (19 -21) . The ligand for ICOS, ICOS-L (also named B7h, LICOS, B7RP-1, B7H-2, and GL-50) does not bind to CD28 or CTLA4 (22) (23) (24) . Similarly, B7-1 and B7-2 are not ligands for ICOS. ICOS-L is more broadly expressed than B7-1 and B7-2. ICOS-L is expressed on professional APC (including dendritic and B cells) and parenchymal cells such as endothelial and epithelial cells, most notably, renal tubular epithelial cells (TEC) (25) (26) (27) (28) .
The consequences of ICOS-ICOS-L signaling in autoimmune diseases are complex. ICOS imparts signals that can either promote or inhibit T cell activation. For example, blocking ICOS during the initiation phase of induced experimental autoimmune encephalomyelitis exacerbates disease, whereas blocking this pathway during the effector phase prevents experimental autoimmune encephalomyelitis (29) . Thus, it is possible that the impact of ICOS blockade may vary depending on the stages of autoimmune disease.
ICOS-L expression displayed on parenchymal cells may regulate T cells within tissues such as the kidney. For example, human endothelial cells that express ICOS-L and class II MHC stimulate resting memory CD4 T cells in the presence of superantigen to generate Th1 and Th2 cytokines (30 C57BL/6J, and C3H/Fej were purchased from The Jackson Laboratory (Bar Harbor, ME) and housed and bred in our pathogen-free animal facility. ICOS null mice were generated as described previously (32) . 
Materials and Methods

Mice
Urinary Protein and Blood Urea Nitrogen
Urine proteins were assessed semiquantitatively by dipstick analysis as described previously (35) and blood urea nitrogen (BUN) levels were measured using a colorimetric analysis kit (Infinity; Thermo Electron, Melbourne, Australia).
Histopathology
Renal. We fixed the kidneys in 10% formalin and prepared and stained sections with hematoxylin-eosin and periodic acid-Schiff reagent. We evaluated renal pathology on a scale of 0 to 3 using coded slides as described previously (35) . We scored glomerular pathology in 20 glomerular cross-sections/kidney, tubular pathology in 200 randomly selected renal cortical tubules/kidney (ϫ400), and perivascular cell accumulation in 10 random inter-and intralobular arteries/kidney (ϫ400) by counting the number of cell layers surrounding the vessel.
Other Tissues. We fixed, prepared, and analyzed the lungs and salivary and lacrimal glands as described previously (35) .
Gross Pathology: Lymphadenopathy, Skin Lesions, and Splenomegaly
We evaluated lymphadenopathy and skin lesions monthly beginning at 2 mo of age and spleen enlargement at the time of killing or death as detailed in previous reports (36) .
Immunohistochemistry
We stained cryostat-cut kidney sections for the presence of macrophages with anti-CD68 Ab (Serotec, Oxford, UK) and for T cells with anti-CD4, anti-CD8, and anti-B220 rat anti-mouse mAb (PharMingen, San Diego, CA) according to a previously described immunoperoxidase method (37) . The immunostaining was analyzed by counting for the presence of CD68-, CD4-, CD8-, and B220-positive cells in 10 randomly selected high-power fields. Of note, we have determined that the B220-positive cells in the kidney are the unique DN T cells and are not B cells (38) .
IgG Isotypes and C3 Deposits within Renal Glomeruli
Kidney cryostat sections (4 m) were stained with FITC-conjugated goat anti-mouse IgG (Molecular Probes, Eugene, OR); FITC-conjugated goat IgG fraction of mouse C3 (Cappel Laboratory, Malvern, PA); and FITC-conjugated rat anti-mouse IgG1, IgG2a, IgG2b, and IgG3 (PharMingen) for 30 min at 37°C. The amount of IgG and C3 lodged within glomeruli was titrated by diluting (1:1000, 1:5000, and 1:10000) the FITC-conjugated IgG. The FITC-conjugated IgG isotypes were titrated (two-fold from 1:50 through 1:1600). Fluorescence intensity within the peripheral glomerular capillary loops and within the mesangium was scored on a scale of 0 to 3 (0, none; 1, weak; 2, moderate; 3, strong). At least 10 randomly selected glomeruli/section were analyzed.
Serum Ig Profiles
We analyzed circulating polyclonal total IgG and IgM and IgG1, IgG2a, IgG2b, and IgG3 isotypes by ELISA. Plates were coated overnight at 4°C with goat anti-mouse Ig capture Ab (Southern Biotechnology Associates, Birmingham, AL) in PBS. The wells were blocked for 2 h with 3% BSA/PBS. We added Ig standards to the plate, using a series of three-fold dilutions, and assessed serum samples using serial dilutions starting at 1:100. Standards and serum samples were incubated overnight at 4°C, and bound Ig was detected with goat antimouse detection Ab conjugated with horseradish peroxidase (Southern Biotechnology Associates) and detected with TMB peroxidase substrate (Kirkegaard Perry Laboratories, Gaithersburg, MD). The absorbance was measured at 450 nm.
We analyzed the anti-dsDNA autoAb isotypes (total IgG, IgG1, IgG2a, IgG2b, IgG3, and IgM) in the sera of ICOSϪ/Ϫ and ICOSϩ/ϩ MRL-Fas lpr mice at five dilutions (1:50, 1:150, 1:450, 1:1350, 1:4050, and 1:12.150) as previously reported (39) .
Flow Cytometry
Measuring the intracellular cytokine production of leukocytes has been described previously (40) . Briefly, we gently dissociated kidneys into single-cell suspensions and lysed the red blood cells. To detect ICOS and ICOS-L on cells in the kidney, we stained the cell suspensions with anti-ICOS PE Ab (0.5 g/ml; eBioscience, San Diego, CA) and anti-ICOS-L PE Ab (0.5 g/ml; eBioscience), respectively. To detect intracellular cytokines, we cultured cells for an additional 4 h in the presence of PMA (10 ng/ml; Sigma-Aldrich, St. Louis, MO) and ionomycin (500 ng/ml; Sigma-Aldrich). Monensin (3 M; Sigma-Aldrich) was added during the last 3 h. We then stained for cell surface markers, including anti-CD4, anti-CD8, anti-B220 Ab-FITC, and anti-TCR-␤ chain Ab-APC (eBioscience). We fixed and permeabilized these cells and stained them with PE-labeled anti-IFN-␥ or anti-TNF-␣ Ab (eBioscience) and fixed them with 1% paraformaldehyde. We analyzed 10,000 cells by flow cytometry.
Statistical Analyses
The data represent the mean Ϯ SEM and were performed by GraphPad Prism Version 3.0 for Macintosh (GraphPad, San Diego, CA). The data shown in Figures 1 and 5 were evaluated using the one way ANOVA (Fisher), and for all other figures, we used the Mann-Whitney U Test. Values of P Յ 0.05 were considered significant unless otherwise stated.
Results
ICOS Is Upregulated and ICOS-L Is Constitutively Expressed during Lupus Nephritis in MRL-Fas lpr Mice
To determine whether ICOS expression in kidney cortex is upregulated in MRL-Fas lpr mice with lupus nephritis, we compared ICOS expression in normal kidneys, from MRL-Fas lpr and C3H/Fej, C57BL/6J mice at 2 mo of age, and ICOS expression in nephritic kidneys that were taken from MRL-Fas lpr at 5 to 6 mo of age ( Figure 1 ). We detected an increase in ICOS expression at the transcriptional (real-time PCR; Figure 1a) (Figure 1b) and protein (Figure 1d ) are constitutively expressed in the renal cortex of 2-mo-old MRL-Fas lpr and C57BL/6J mice that have normal kidneys. However, expression is not significantly increased in the MRL-Fas lpr mice at 5 to 6 mo of age. Thus, intrarenal ICOS-L does not vary with advancing lupus nephritis.
Intrarenal Macrophages and T Cells Are not Diminished in ICOSϪ/Ϫ MRL-Fas lpr Kidneys
We previously determined that macrophages and T cells accumulate in the MRL-Fas lpr kidney with nephritis (35, 38) . We found that the accumulation of macrophages (CD68) and T cells (CD4, CD8, and DN) in the glomerular and interstitial regions are similar in the ICOSϪ/Ϫ MRL-Fas lpr as compared with the ICOSϩ/ϩ MRL-Fas lpr mice at 6 mo of age ( Figure 2) . Therefore, genetic disruption of ICOS in MRL-Fas lpr mice does not prevent 
Frequency of Intrarenal Th1 and Other T Cell Subsets that Express IFN-␥ and TNF-␣ Is Enhanced in ICOSϪ/Ϫ MRLFas lpr Mice
To determine whether ICOS regulates T cells within the kidney, we compared the amounts of Th1 cytokines, IFN-␥, and TNF-␣ expressed by T cell populations (CD4) and other T cell subsets (CD8 and DN) that were freshly isolated from ICOSϪ/Ϫ MRL-Fas lpr and WT kidneys. We found that the frequency of intrarenal CD4 T cells that express IFN-␥ and TNF-␣ in ICOSϪ/Ϫ MRL-Fas lpr mice was significantly higher than in the WT strain (Figure 3, 1) . Similarly, the frequency of CD8 T cells and DN (B220ϩ TCRϩ) cells that generate IFN-␥ increased significantly as compared with the WT (Figure 3, 2  and 3 ). Although the frequency of TNF-␣ in CD8 T cells seemed to be greater than the WT, it was NS (P ϭ 0.19; Figure 3, 2) . The frequency of B220ϩTCRϩ cells that expressed TNF-␣ in ICOSϪ/Ϫ MRL-Fas lpr and WT remained similar (P ϭ 0.77; Figure 3, 3) . By comparison, the frequency of T cells (CD4, CD8, and B220ϩTCRϩ) that generated IFN-␥ and TNF-␣ in normal kidneys (C57BL/6J) was almost negligible (Յ0.14% of total kidney cells, n ϭ 4/group). Thus, eliminating ICOS in MRLFas lpr mice increases the frequency of intrarenal T cell populations that produce IFN-␥ and TNF-␣.
The expression of Th2 cytokines such as IL-4 and IL-10 are increased in T cells after ICOS co-stimulation (41) . Therefore, we compared the frequency of CD4, CD8, and B220ϩTCRϩ cells that generate IL-4 and IL-10 in the kidney and spleen of ICOSϪ/Ϫ MRL-Fas lpr and WT mice (n ϭ 3/group). We were unable to detect T cell subsets that expressed IL-4 or IL-10 in the kidney of either strain; thus, renal disease in the MRL-Fas lpr strain is Th1 and not Th2 driven. However, we determined that the frequency of IL-4 -and IL-10 -producing CD4, CD8, and B220ϩTCRϩ cells in the spleen was similar in the ICOSϪ/Ϫ MRL-Fas lpr and WT mice at 6 mo of age (data not shown). We conclude that eliminating ICOS increases the frequency of Th1 and other T cell subsets that produce IFN-␥ and TNF-␣ but does not alter Th2 cells in the MRL-Fas lpr strain.
Eliminating ICOS Suppresses Serum Ig and AutoAb Titers in MRL-Fas lpr Mice
Elevated Ig and Ig class switching are hallmarks of autoimmune disease (4, 42) . B cells are responsible for the production of these Ab after help from autoreactive T cells (43, 44) . To determine whether ICOS alters these parameters in MRL-Fas lpr mice, we compared circulating Ig and anti-dsDNA isotype titers in ICOSϪ/Ϫ MRL-Fas lpr and WT strains (n ϭ 5/group, 6 mo of age). Serum titers of total IgG and IgG isotypes (IgG1, IgG2a, and IgG2b) but not IgG3 and IgM are markedly reduced (69, 74, and 77%, respectively) in ICOSϪ/Ϫ MRL-Fas lpr mice as compared with the WT strain at 6 mo of age (Figure 4a) . 
Despite Reduction in Serum IgG Isotype Titers, Similar Amounts of These Isotypes and Complement Lodge in ICOSϪ/Ϫ MRL-Fas lpr and WT Kidneys
The deposition of IgG and complement (C3) within glomeruli is a characteristic feature of renal disease in MRL-Fas lpr mice (45, 46) . To determine whether the decrease in circulated Ig and dsDNA autoAb titers (total IgG, IgG1, IgG2a, and IgG2b) translated into a decrease in the deposition of these polyclonal and autoAb Ig in glomeruli, we compared ICOSϪ/ϪMRL-Fas lpr and WT kidneys. The fluorescence intensity of IgG, C3, and IgG isotypes (IgG1, IgG2a, and IgG2b) within the glomerular peripheral capillary loops and the mesangium was similar in ICOSϪ/Ϫ MRL-Fas lpr and WT strains (Figure 4c ). In addition, the titers of IgG3 in glomeruli, not reduced in the serum of ICOSϪ/Ϫ MRL-Fas lpr mice, was equivalent in ICOSϪ/Ϫ MRLFas lpr mice and WT mice (Figure 4c) . Thus, despite a decrease in serum IgG and dsDNA autoAb isotype titers in the ICOSϪ/Ϫ MRL-Fas lpr strain, the amount of these IgG and C3 lodged within glomeruli was equivalent.
Eliminating ICOS in MRL-Fas lpr Mice Does not Alter Severity or Tempo of Renal Pathology
To evaluate whether genetic disruption of ICOS prevents or exacerbates lupus nephritis, we compared renal pathology in ICOSϪ/Ϫ MRL-Fas lpr and WT strains at 6 mo of age. ICOSϪ/Ϫ MRL-Fas lpr and WT mice had severe glomerular, tubular, and perivascular pathology as compared with age and gendermatched MRLϩ/ϩ and C57BL/6J mice with normal kidneys ( 
Proteinuria and BUN Levels Are Similar in ICOSϪ/Ϫ MRL-Fas lpr as Compared with WT Mice
To determine whether genetic disruption of ICOS in the MRL-Fas lpr strain alters renal function, we evaluated the urinary protein and BUN levels in ICOSϪ/Ϫ MRL-Fas lpr and WT strains monthly from 2 to 6 mo of age. The urinary protein levels in ICOSϪ/Ϫ and WT mice, undetectable at 2 mo of age, increased from 2 to 6 mo of age (Figure 6a ) in both strains. Similarly, the BUN rose from 3 to 6 mo in both the ICOSϪ/Ϫ MRL-Fas lpr and WT strains (Figure 6b ). However, we did not detect a difference in the proteinuria or BUN levels between ICOSϪ/Ϫ MRL-Fas lpr and WT strains. Thus, eliminating ICOSϪ/Ϫ in MRL-Fas lpr mice does not alter proteinuria and BUN levels.
Systemic Pathology Is Similar in ICOSϪ/Ϫ MRL-Fas lpr
Mice and WT Mice
Several tissues in addition to the kidney, including lungs, salivary and lacrimal glands, and skin, are targeted for auto- Figure 3 . There is an increased frequency of intrarenal Th1 cells in ICOSϪ/Ϫ MRL-Fas lpr mice as compared with the WT strain (6 mo of age). The frequency of intrarenal CD4 cells that generate IFN-␥ and TNF-␣ is increased as compared with the WT strain (1; *P Յ 0.05). Similarly, the frequency of CD8 and B220 T cells that generate IFN-␥ is enhanced in ICOSϪ/Ϫ MRL-Fas lpr as compared with WT mice (2, 3; *P Յ 0.05). While the frequency of CD8 that generate TNF-␣ tends to be higher, it is NS (2; P ϭ 0.19). Of note, because the frequency of intrarenal T cell populations that generate IFN-␥ and TNF-␣ was similar in age-matched ICOSϩ/ϩ MRL-Fas lpr (N5) and MRL-Fas lpr mice (n ϭ 3 and n ϭ 5, respectively), we combined the data.
immune destruction in the MRL-Fas lpr strain (5). We detected similar numbers of infiltrating peribronchiolar and perivascular leukocytes in the lungs of ICOSϪ/Ϫ MRL-Fas lpr and WT strains (6 mo of age; Figure 7a ). In addition, the extent of leukocytic infiltration in the salivary and lacrimal glands in ICOSϪ/Ϫ and WT mice was equivalent (6 mo of age; Figure 7 , b and c). The incidence (50% at 4 mo of age, 75% at 5 mo of age, and 90% at 6 mo of age) and severity of skin lesions also did not differ in the ICOSϪ/Ϫ MRL-Fas lpr and WT strains. Finally, the lymphadenopathy and splenomegaly were similar in the ICOSϪ/Ϫ MRL-Fas lpr and WT strains (n ϭ 12 to 15/group; data not shown). Taken together, these data indicate that genetic disruption of ICOS is not sufficient to alter systemic pathology in MRL-Fas lpr mice.
Discussion
Consistent with the known requirement of ICOS for T celldependent primary B cell responses (32), we have now determined that disruption of the ICOS gene in MRL-Fas lpr mice serves to suppress serum polyclonal Ig and dsDNA autoAb isotype (G1, G2a, and G2b) titers that rise with advancing disease. Importantly, this suppression in circulating IgG and autoAb isotypes did not translate into improved renal or systemic pathologic consequences. Renal disease (pathology and function) and the systemic illness (inflammation and the lymphoproliferative disorder) were not deterred in the ICOSϪ/Ϫ MRL-Fas lpr strain. Thus, serum IgG and dsDNA autoAb titers and lupus nephritis are uncoupled in ICOSϪ/Ϫ MRL-Fas lpr mice. These findings complement our previous data in which nephritis is suppressed in MCP-1 null and IL-12 null MRLFas lpr mice, although the serum IgG and autoAb remain elevated (33, 36) . Circulating autoAb are frequently monitored as prognostic indicators of autoimmune diseases. Our findings draw attention to the potential danger in relying on serum Ig and autoAb titers to monitor the course of autoimmune disease.
What are the consequences of a reduction in serum polyclonal IgG and autoAb isotype titers on Ig deposition in glomeruli in MRL-Fas lpr mice that lack ICOS? Despite a reduction of these serum Ab titers, the amounts of these specific IgG isotypes that are lodged in glomeruli are not diminished in ICOS null MRL-Fas lpr . There are several plausible explanations. Given that there is a finite amount of Ab that can lodge in glomeruli, it is possible that the serum Ab titers in ICOSϪ/Ϫ MRL-Fas lpr mice exceed this finite amount; hence, the glomeruli are saturated with Ab despite the reduction in serum Ab titers as compared with WT mice. Alternatively, we favor the possibility that the pathogenic Ab that deposit in glomeruli are a relatively small subpopulation of those in the circulation. In either case, it is clear that the titers of Ig isotypes are not necessarily linked to the quantity of Ab that deposit in renal glomeruli.
In keeping with the concept that ICOS stimulation enhances Th2 differentiation, we observed an increased frequency of intrarenal Th1 cells in ICOS null MRL-Fas lpr . The frequency of IFN-␥-and TNF-␣-expressing CD4 T cells in the kidney was enhanced in ICOSϪ/Ϫ MRL-Fas lpr as compared with WT mice. In addition, we detected a substantial rise in the frequency of IFN-␥ and TNF-␣ expression in other intrarenal T cell populations (CD8 and DN). On the basis of this finding and coupled with evidence that (1) IFN-␥ and TNF-␣ are nephritogenic in lupus mice (38, 47) , (2) T cells (CD4, CD8, and DN) are required for lupus nephritis (6) , and (3) ICOS may inhibit tubular epithelial cell-mediated immune activation in the kidney in vitro (31), we might have anticipated that the elevated frequency of Th1 and other IFN-␥-and TNF-␣-expressing T cells would hasten the onset and worsen lupus nephritis in the absence of ICOS. This is not the case. Clearly, the lupus syndrome is accompanied by a variety of autoreactive T cell and autoAb parameters. The precise role and contribution to lupus and renal disease of each parameter are uncertain. Taken together, our findings underscore the danger of relying on measurements of individual parameters to predict disease outcome.
Before this report, there was conflicting evidence regarding the importance of the ICOS pathway as a therapeutic target for systemic autoimmune diseases such as lupus. For example, in a mercury chloride-induced model of systemic autoimmune disease, as defined by a rise in serum anti-nucleolar Ab (48), ICOS blockade with anti-ICOS Ab suppressed the rise in these serum autoAb. This suggested that targeting the ICOS pathway had therapeutic promise for systemic autoimmune illnesses. However, a quantitative reduction of serum autoAb alone, as we have shown, does not necessarily lead to amelioration of tissue injury, and chronic mercury chloride-induced immune mediated nephritis was not explored. However, treatment of a spontaneous model of systemic autoimmune lupus, the NZB/W, with anti-ICOS-L Ab but not with anti-ICOS Ab before and during disease resulted in a reduction in anti-dsDNA Ab, suppression of nephritis, and extended survival (49) . The different outcomes of administration of anti-ICOS and anti-ICOS-L Ab might reflect differences in affinity or half-life of these Ab. However, our studies using ICOSϪ/ϪMRL-Fas lpr mice are consistent with the anti-ICOS Ab studies, suggesting that there are different biologic roles of ICOS and ICOS-L. Furthermore, studies are needed to understand these biologic differences. Further studies are also required to validate whether ICOS-L is a therapeutic target including ICOS-L null and Ab blockade approaches in the MRL-Fas lpr strain. Finally, we compared nephrotoxic serum nephritis, another T cell-dependent immunemediated renal disease, in ICOSϪ/Ϫ mice and WT mice. Renal pathology and function were similar in the ICOSϪ/Ϫ as compared with WT mice (data not shown). Thus, on the basis of our studies using ICOS null MRL-Fas lpr mice and nephrotoxic serum nephritis, we suggest that ICOS monotherapy is not a promising therapeutic target for lupus or immune-mediated 
